Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light

BACKGROUND: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment. OBJECTIVE: To assess the value of serum glial fibrillary acidic protein (sGFAP) as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wessels, Mark HJ, Van Lierop, Zoë YGJ, Noteboom, Samantha, Strijbis, Eva MM, Heijst, Johannes A, Van Kempen, Zoé LE, Moraal, Bastiaan, Barkhof, Frederik, Uitdehaag, Bernard MJ, Schoonheim, Menno M, Killestein, Joep, Teunissen, Charlotte E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503252/
https://www.ncbi.nlm.nih.gov/pubmed/37530045
http://dx.doi.org/10.1177/13524585231188625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503252/
https://www.ncbi.nlm.nih.gov/pubmed/37530045
http://dx.doi.org/10.1177/13524585231188625

Ejemplares similares